ArticleArchives of dermatological research2025
MeCP2 promotes keloid progression by regulating ADAM12 expression and Wnt/β-catenin pathway.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comment on "Distinct Molecular Signature of Earlobe Keloids: Integrated Transcriptomic Analysis of Extracellualr Matrix, Metalloproteinase, and Metabolic Path".Aesthetic plastic surgery · 2026Article
- Distinct Molecular Signature of Earlobe Keloids: Integrated Transcriptomic Analysis of Extracellualr Matrix, Metalloproteinase, and Metabolic Pathways.Aesthetic plastic surgery · 2026Article
- Cellular Senescence in Keloid Pathology: Mechanisms, Biomarkers, and Potential Therapeutic Targets.Biomedicines · 2026Review
- Histone modifications in skin fibrosis: linking immune dysregulation, metabolic reprogramming, and persistent fibrotic remodeling.Frontiers in immunology · 2026Review
- A panoramic analysis of keloid pathogenesis: multidimensional network regulation of genetics-immunity-metabolism-mechanical force.Frontiers in immunology · 2026Review
- Exploring putative links between gut microbiota and allergic rhinitis: insights from Mendelian randomization and multi-transcriptome integration.AMB Express · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMethyl-CpG binding protein 2 (MeCP2) has been reported to participate in the progression of human diseases. In this study, we aimed to explore the functions and related mechanisms of MeCP2 in keloid progression.
methodsExpression of MeCP2 and A Disintegrin and Metalloprotease 12 (ADAM12) was measured by qRT-PCR and western blot assay. Cell proliferation was explored by CCK-8 assay. Cell migration and invasion were investigated by transwell assay. Cell apoptosis was analyzed by flow cytometry analysis. The relation between ADAM12 and MeCP2 was analyzed by CHIP RT-PCR assay and dual-luciferase reporter assay.
resultsADAM12 was highly expressed in keloid tissues and keloid fibroblasts. Silencing of ADAM12 suppressed the proliferation, migration, invasion, ECM accumulation, facilitated the apoptosis and blocked Wnt/β-catenin pathway in keloid fibroblasts. Furthermore, we verified that MeCP2 could modulate ADAM12 expression by binding to its promoter. MeCP2 knockdown inhibited keloid fibroblasts proliferation, migration, invasion and ECM accumulation, with ADAM12 overexpression ameliorated the effects. Besides, MeCP2 silencing inhibited Wnt/β-catenin pathway by altering ADAM12 expression.
conclusionMeCP2 regulated ADAM12 expression and Wnt/β-catenin pathway to promote cell proliferation, migration, invasion and ECM accumulation in keloid fibroblasts.
Indexed as
Identifiers
40119949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.